Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches

The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception

(2013) Michael W. Weiner et al.   Alzheimers & Dementia

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

(2013) Ralf Gold et al.   LANCET

Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis

(2013) Joel P. Thompson et al.   PHARMACOECONOMICS

Demystifying trial networks and network meta-analysis

(2013) E. J. Mills et al.   BMJ-British Medical Journal

Alemtuzumab in multiple sclerosis: latest evidence and clinical prospects

(2013) Onajite Kousin-Ezewu et al.   Therapeutic Advances in Chronic Disease

Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis

(2013) Annie Hawton et al.   Applied Health Economics and Health Policy

Cost-Effectiveness of Early Initiation of Fingolimod Versus Delayed Initiation After 1 Year of Intramuscular Interferon Beta-1a in Patients with Multiple Sclerosis

(2012) Neetu Agashivala et al.   CLINICAL THERAPEUTICS

Cost-Effectiveness Analysis of Interferon Beta-1b for the Treatment of Patients With a First Clinical Event Suggestive of Multiple Sclerosis

(2012) John P. Caloyeras et al.   CLINICAL THERAPEUTICS

Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States

(2012) Feng Pan et al.   CLINICAL THERAPEUTICS

Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4

(2012) Jonathan Karnon et al.   VALUE IN HEALTH

Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7

(2012) David M. Eddy et al.   VALUE IN HEALTH

Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States

(2012) Soyon Lee et al.   JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients

(2012) Rainel Sánchez-de la Rosa et al.   JOURNAL OF MEDICAL ECONOMICS

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis

(2012) Stephanie R. Earnshaw et al.   Applied Health Economics and Health Policy

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials

(2011) James E. Signorovitch et al.   CURRENT MEDICAL RESEARCH AND OPINION

Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study

(2011) K. Noyes et al.   NEUROLOGY

Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis

(2011) Ken O’Day et al.   JOURNAL OF MEDICAL ECONOMICS

A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective

(2010) Mark Nuijten et al.   CLINICAL THERAPEUTICS

New perspectives in the natural history of multiple sclerosis

(2010) H. Tremlett et al.   NEUROLOGY

No Head-to-Head Trial? Simulate the Missing Arms

(2010) J. Jaime Caro et al.   PHARMACOECONOMICS

Cost-effectiveness of four immunomodulatory therapies for relapsingremitting multiple sclerosis: A Markov model based on data a Balkan country in socioeconomic transition

(2010) Slobodan Jankovic et al.   Vojnosanitetski Pregled

The Multiple Sclerosis Risk Sharing Scheme Monitoring Study – early results and lessons for the future

(2009) Mark Pickin et al.   BMC Neurology

Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis

(2009) P Tappenden et al.   BONE MARROW TRANSPLANTATION

Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis

(2009) Evelyn Chiao et al.   CURRENT MEDICAL RESEARCH AND OPINION

Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon β-1b

(2009) Carlo Lazzaro et al.   NEUROLOGICAL SCIENCES

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

(2009) Ray Gani et al.   PHARMACOECONOMICS

Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a

(2009) Shien Guo et al.   PHARMACOECONOMICS

Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population

(2009) Paul Tappenden et al.   VALUE IN HEALTH

The cost effectiveness and budget impact of natalizumab for formulary inclusion

(2009) Justin Bakhshai et al.   JOURNAL OF MEDICAL ECONOMICS

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden

(2008) G Kobelt et al.   Multiple Sclerosis Journal

Use of Indirect and Mixed Treatment Comparisons for Technology Assessment

(2008) Alex Sutton et al.   PHARMACOECONOMICS